IN VITRO ANTIUROLITHIATIC ACTIVITY OF MACERATED AQUEOUS EXTRACT OF TERMINALIA BELERICA BY USING TURBIDITY METHOD
Objective: To evaluate the anti-urolithiatic activity of macerated aqueous extract of Terminalia belerica by using turbidity method
Method: The present study was used to study the inhibitory effect of the Terminalia belerica on urinary stone formation. The aim of study was to examine the In vitro antiurolithiatic activity of macerated aqueous extract of T.belerica was to estimate inhibitory activity of aqueous extract on the formation of urinary stone. Cystone was used as a positive control. Anti urolithiatic study was performed by turbidity method.
Result: The percentage inhibition shown by aqueous extract at 20μg/ml was 60% and with almost constant inhibition at 100μg/ml and 200μg/ml ranging between 72% and 80%. The percentage inhibition showed by aqueous extract of Terminalia belerica has significant compared to standard drug.
Conclusion: In future this drug can be performed in vitro and clinical study beneficial for people with avoiding adverse effect of modern medicinal drugs
2. Khan MA, Pradhan D. Antiurolithiatic activity of ceropegia bulbosa extract in rats. Der Pharm Sin 2013;3:148-52.
3. Singh SK. Disease monograph-5; Urolithiasis; central council for research in homeopathy publication. Deluex Printery; 2011. p. 4.
4. Awari MD, Mute V, Babhale SP, Chaudhar PS. Antilithiatic effect of achyranthesaspera linn. leaves extract on ethylene glycol induced nephrolithiasis. J Pharm Res 2009;2:994-7.
5. Shashi A, Jain SK, Verma A, Kumar M, Sabharwal M. Pathophysiology of kidney. gallbladder and urinary stones treatment with herbal and allopathic medicine; a review. Asian Pac J Trop Dis 2013;3:496-504.
6. Tiselius HG. Etiology and investigation of stone disease, curriculum in urology. Eur Urol 1998;2:1-7.
7. Mistry J, Danpure CJ, Chalmers RA. Hepatic D-glycerates dehydrogenase and glyoxylate reductase deficieny in primary hyperoxaluria type 2. Biochem Soc Trans 1988;16:626-7.
8. Hobarth K, Hofbauer J, Szabo N. Value of repeated analysis of 24h urine in recurrent calsiumurolythyasis. Urology 1994;44:20-5.
9. Hess B, Hasler Strub U, Askermann D, Jaeger PH. Metabolic evalulationn of patient with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 1997;12:1362-8.
10. Tiselius HG. Solution chemistry of supersatutartion. In: Kidney Stone: Medical and Surgical Management. FL Coe, MJ Favus, CYC Pak, HG Parks, GM Preminger. (Eds) Lippincott-Raven Publishers, Philadelphia; 1996. p. 31, 33-64.
11. Khan AU, Gilani AH. Pharmacodynamic evaluation of terminalia bellirica for its antihypertensive effect. J Food Drug Anal 2008;16:6-14.
12. Kaur S, Jaggi RK. Antinociceptive activity of chronic administration of different extracts of Terminalia bellirica roxb and terminaliachebula retz. Fruits Indian J Exp Biol 2010;48:925-30.
13. Saraswathi MN, Karthikeyan M, Kannan M, Rajasekar S, Terminalia Bellirica. Roxb-a phytopharmacological review. Int J Res Pharm Biomed Sci 2012;3:96-9.
14. Frawley D, Vasant L. The yoga of herbs: an ayurvedic guide to herbal medicine. Santa Fe: Lotus Press; 1986.
15. Selvan AT, Jayalaxmi B, Ashvini RP, Suthakaran R, Vishwanath. Antiurolithiatic activity of triphalakarpachooranam. J Adv Pharm Edu Res 2013;3:267-72.
16. Anu V, Pavithra P. In vitro anthelmintic activity of macerated ethanolic extracts of roots of holostema adakodien. Int J Pharmacogn 2019;6:30-2.
17. Bensatal A, OUahrani MR. Inhibition of crystalisation of calcium oxalate by the extraction of tamarixgallica L. Urol Res 2008;36:283-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.